Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.73 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25185197 | 0.84 | KIF11 (0.59) | KIF11DAOKDM1AP2RX7FFAR1 | |
| SCHEMBL93061 | 0.83 | KIF11 (0.58) | KIF11P2RX7CYP4F2CYP4A11 | |
| SCHEMBL29875866 | 0.83 | KIF11 (0.58) | KIF11P2RX7CYP4F2CYP4A11 | |
| SCHEMBL10299813 | 0.83 | KIF11 (0.58) | KIF11P2RX7CYP4F2CYP4A11 | |
| SCHEMBL30368288 | 0.83 | KIF11 (0.56) | KIF11DAOCYP4F2CYP4A11RXRA | |
| SCHEMBL1994099 | 0.83 | KIF11 (0.56) | KIF11DAOCYP4F2CYP4A11RXRA | |
| SCHEMBL17414243 | 0.82 | KIF11 (0.51) | KIF11DAOCYP4F2CYP4A11RXRA | |
| SCHEMBL79124 | 0.81 | KIF11 (0.56) | KIF11DAOKDM1AP2RX7FFAR1 | |
| SCHEMBL27595825 | 0.81 | KIF11 (0.51) | KIF11DAOP2RX7CYP4F2CYP4A11 | |
| SCHEMBL15813735 | 0.81 | KIF11 (0.64) | KIF11DAOFFAR1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810572-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | claimed |
| EP-2421847-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| CN-119569635-A | Biaryl ring inhibitors targeting c-Myc proteins | 上海深势唯思科技有限责任公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4484407-A2 | (METH)ACRYLATE COMPOUND, ADDITIVE FOR OPTICAL RESIN, OPTICAL ELEMENT, AND OPTICAL DEVICE | NIKON CORPORATION (JP) | 2025-01-01 | — | — | EP | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| CN-1503774-A | Carboxylic acid derivatives and salts thereof | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-20020022604-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | PHAMACIA CORPORATION | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | CACNA1G, CACNA1H, CACNB2 | KIF11 3285/4885DAO 519/4885KDM1A 2978/4885 |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | KIF11 4205/4885DAO 4086/4885KDM1A 4513/4885 |
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | KIF11 4335/4885DAO 865/4885KDM1A 405/4885 |
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | KIF11 3185/4885DAO 1499/4885KDM1A 1433/4885 |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | KIF11 4638/4885DAO 1164/4885KDM1A 2052/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | KIF11 4205/4885DAO 4086/4885KDM1A 4513/4885 |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | KIF11 4628/4885DAO 2258/4885KDM1A 2450/4885 |
| US-20020022604-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, F2 | KIF11 4873/4885DAO 691/4885KDM1A 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.